Compare DexCom, Inc. (DXCM) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vipshop Holdings Ltd - ADR — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.81B), while Vipshop Holdings Ltd - ADR trades at $12.71 (market cap $6.07B). The key difference: DexCom, Inc. is far larger — about 5.2× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays a 4.86% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Vipshop Holdings Ltd - ADR for 49 Days on average.
| DXCM | VIPS | |
|---|---|---|
Market Cap | $31.81B | $6.07B |
Volume | 2,861,821 | 3,134,219 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $20.29 |
52-Week Low | $54.84 | $12.09 |
Typical Hold Time | 62 Days | 49 Days |
Enterprise Value | $31.26B | $2.90B |
Dividend Yield | — | 4.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 1.22% amid a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $0.70 exceeding expectations of $0.611. Revenue growth remains robust, climbing from $2.9B in 2022 to $4.7B in 2025, while net income margins improved to 17.93%. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
Wall Street maintains a bullish stance with 81% buy ratings and a $95.07 consensus price target, representing 13% upside potential. Key risks include competitive pressures in CGM markets and reimbursement challenges. The company's strong cash flow generation and expanding market opportunity in diabetes technology support long-term growth prospects despite current technical weakness.
Vipshop (VIPS) trades at $12.72, down 0.24% on the day, with a bullish overall technical signal. The stock appears undervalued with a P/E of 4.12 and P/S of 0.41, supported by strong profitability metrics including a 9.82% net income margin and 24.44% ROE. Recent Q2 2026 earnings missed expectations, with revenue of $105.92 billion in 2025 showing a slight decline, but net income remains robust at $7.24 billion. Analyst consensus is bullish with a $16.17 price target.
The outlook for VIPS is mixed; attractive valuation and strong cash flow generation offer upside potential, but recent earnings misses and a challenging consumer environment pose near-term risks. Investor sentiment is cautiously optimistic, with 53.57% of analysts rating it a buy, though growth stagnation remains a key concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
